UNSPSC 51294903: Dosulepin

This classification denotes an anxiolytic with the molecular formula C19H21NS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W13O82Z7HL, chemically known as 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenzo(b,e)thiepine hydrochloride but generally known as dosulepin, which bears US NIH Compound Identifier 5282425. European Medicines Agency schedules Dosulepin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06377MIG.

World Health Organization schedules dosulepin in its Anatomical Therapeutic Chemical (ATC) Classification. DOSULEPIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dosulepin under HS 29349990 and SITC 51579. SMILES: Cl.S1Cc2c(/C(=C/CC[NH](C)C)c3c1cccc3)cccc2.

UNSPSC 51294903 Dosulepin is a Commodity code, but recent state and local procurement activity under this code does not involve dosulepin itself. Instead, issuing bodies are purchasing naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing frameworks. The mismatch between the code's nominal scope and actual buying activity reflects how state and local procurement systems sometimes tag opportunities with codes that do not align with the products or services being solicited. State and local health departments, county community health agencies, and multi-state cooperative purchasing alliances are the primary issuing bodies, seeking to acquire pharmaceutical inventory and harm-reduction supplies through fixed-fee or competitive pricing arrangements. Vendors typically must meet compliance requirements including FDA certification, cGMP standards, Drug Supply Chain Security Act adherence, E-Verify employment verification, and workers' compensation and professional liability insurance.

Recent activity spans Florida and multi-state cooperative procurement vehicles anchored in Minnesota and Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, and quarterly deliveries to the Seminole County Community Health Building. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendors to maintain relationships with authorized wholesalers AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson, with evaluation weighted 75 percent on price competitiveness. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities for a planned Therapeutic Pharmacy Initiative, representing exploratory procurement ahead of formal solicitation. The code shows limited direct activity aligned to dosulepin procurement and should be pursued only when sourcing broader pharmaceutical or health-supply inventory through state and local cooperative or direct-buy channels.